Skip to content

PARACELSUS PHARMA PROJECTS

Active Private limited company (pre-2019)founded 2001active for 25 yearsAalterveld 26, 9880 AalterKBO/BCE: BE 0475.409.569

Lifetime

20 annual accounts with figures on one time axis, 24 filings since 2002
peak of €72,263 in 2006
€9,489▼ 44.0%
lowest -€26,399 in 2019
-€10,092▼ €7,587
peak of €221,196 in 2012
€107,010▼ 8.6%
€90,170▼ 18.3%
Board1 name since 2009
1 director
Documentsfilings and deeds
29-07-20262 days before the deadline
2025micro format
Gross margin from €16,954 to €9,489Loss of €10,092Debts from €110,433 to €90,170Cash from €12,006 to €1,284

Key points

from the 2025 annual accounts

Equity

€107,010 from €221,196 in 2012

Equity fell by 52% in 13 years.

Losses

-€114,186 in 13 years
201320152017-26,399201920212023-10,0922025

Every financial year from 2013 to 2025 closed with a loss. 2019 was the heaviest.

Turnover

≈ €100,000 estimated

The micro format states no turnover.

Filings

24 annual accounts since 2002
AprilJune31 JulyOctober20102020

The 2017 accounts came 24 days late. The other nine of the last ten were filed on time.

Board

1 left

1 director left, the latest on 01-05-2026. 1 is in office now.

Position in the sector

-€10,092

Lower net result than 82% of companies in retail trade. The sector median is €4,726, over 25,385 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 12,346 companies had the same profile as PARACELSUS PHARMA PROJECTS has now. Each dot stands for 31 companies, two years later.

90.1%
were still trading
8.7%
stopped another way
0.7%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a small loss

Another 0.5% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 12,346 companies, not a prediction for PARACELSUS PHARMA PROJECTS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 26-02-2009
Board & ownership

Recent changes

resigns as manager General meeting of 01-05-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0475409569
appointed as manager Gazette deed
resigns as manager Gazette deed
All 32 events

Comparable companies

same main activity, similar in size and age
Company
PARACELSUS PHARMA PROJECTS Aalter €197,179 €9,489 54.3% -
Un Coquelicot Orange Courcelles €150,628 €10,202 97.1% -
OBIPHAR Frameries €218,848 €6,330 54.3% -
Apotheek Els De Smedt Beveren-Kruibeke-Zwijndrecht €157,911 €12,944 2.9% -
CLEMENT PHARMA SERVICES Meise €151,301 €13,007 71.9% -
PHARMACIE SAINTE-VERONIQUE Liège €252,381 €11,341 20.4% -
AONA Roeselare €290,456 €8,140 22.9% -

These companies have the same main activity as PARACELSUS PHARMA PROJECTS: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €151,000 and €290,000, founded between 1989 and 2007.

Official details

Source: KBO
Status
Active since 01-08-2001Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.116.584.4419880 Aalter, since 21-09-2001
Financial year end
31 December
Peppol
Reachable since 12-01-2026
Company details

Annual accounts 2025

€197,179▼ 13.3%
Filing
Filed on 29-07-2026, 2 days before the end of the filing period
Financials

Insights on PARACELSUS PHARMA PROJECTS

PARACELSUS PHARMA PROJECTS files the micro format. That format states no turnover. The gross margin fell from €72,263 in 2006 to €9,489 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PARACELSUS PHARMA PROJECTS

What is the company number of PARACELSUS PHARMA PROJECTS?
The company number of PARACELSUS PHARMA PROJECTS is 0475.409.569. The VAT number is the same number with BE in front: BE 0475.409.569.
Where is PARACELSUS PHARMA PROJECTS based?
The registered office is at Aalterveld 26, 9880 Aalter.Company details
What does PARACELSUS PHARMA PROJECTS do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PARACELSUS PHARMA PROJECTS?
PARACELSUS PHARMA PROJECTS is a private limited company (pre-2019) (BVBA).
When was PARACELSUS PHARMA PROJECTS founded?
PARACELSUS PHARMA PROJECTS was founded on 01-08-2001.
Is PARACELSUS PHARMA PROJECTS still active?
Yes, PARACELSUS PHARMA PROJECTS is an active enterprise in the KBO register.
What is the turnover of PARACELSUS PHARMA PROJECTS?
The turnover in financial year 2025 is about €100,000. This figure is estimated from the gross margin of €9,489 and 137 comparable companies (NACE 477). It probably lies between €36,000 and €210,000. It is a rough estimate.Financials
Is PARACELSUS PHARMA PROJECTS profitable?
In financial year 2025, PARACELSUS PHARMA PROJECTS made a loss of €10,092.
Where can I find the annual accounts of PARACELSUS PHARMA PROJECTS?
PARACELSUS PHARMA PROJECTS filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PARACELSUS PHARMA PROJECTS due?
PARACELSUS PHARMA PROJECTS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.